Targeted immunotherapy for staphylococcal infections : focus on anti-MSCRAMM antibodies

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Michael Otto

Abstract

Staphylococcal infections represent an enormous burden to the public health system in the US and worldwide. While traditionally restricted to the hospital setting, highly virulent strains have recently emerged that may cause severe, even fatal, disease in healthy adults outside healthcare settings. This situation, together with the increasing resistance to many antibacterials in a wide variety of staphylococcal strains, requires that vaccine development for staphylococcal diseases be re-evaluated. Finding a vaccine for staphylococci is not trivial, as protective immunity to staphylococcal infections does not appear to exist at a significant degree, which may be partly due to the fact that our immune system is in constant contact with staphylococcal antigens and many strains are commensal organisms on human epithelia. Furthermore, the most virulent species, Staphylococcus aureus, produces protein A, a powerful means to evade acquired host defense. While two high-profile vaccine preparations have failed clinical trials within the last few years, promising results from novel approaches based on the combination of systematically selected antigens have been reported. These combinatory vaccines target microbial surface components rec...Continue Reading

References

Apr 1, 1984·Diagnostic Microbiology and Infectious Disease·R D ArbeitJ B Robbins
Sep 15, 1995·The Journal of Biological Chemistry·K JönssonM Höök
May 23, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·I RaadK Rolston
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Feb 26, 1999·Trends in Microbiology·T J Foster, M Höök
Jan 4, 2001·The New England Journal of Medicine·C von EiffG Peters
Mar 2, 2002·The Lancet Infectious Diseases·K Hiramatsu
Apr 5, 2002·Microbes and Infection·Cuong Vuong, Michael Otto
May 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Hildegard EtzAndreas Meinke
May 16, 2002·Vaccine·Eric BrouilletteBrian G Talbot
Sep 10, 2002·The Journal of Biological Chemistry·M Gabriela BowdenMagnus Hook
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cassandra D SalgadoDavid P Calfee
Jan 17, 2004·Clinical Microbiology Reviews·Katherine O'Riordan, Jean C Lee
Feb 10, 2004·Frontiers in Bioscience : a Journal and Virtual Library·Michael Otto
Apr 23, 2004·Infection and Immunity·Anna RennermalmJan-Ingmar Flock
Jan 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jesse S WrightRichard P Novick
Feb 4, 2005·The New England Journal of Medicine·Sophia V KazakovaDaniel B Jernigan
Apr 9, 2005·The New England Journal of Medicine·Henry F Chambers
Apr 22, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nolan E LeePaul A Simon
Sep 24, 2005·Infection and Immunity·Bret R SellmanSteve M Baker
Dec 3, 2005·Nature Reviews. Microbiology·Timothy J Foster

❮ Previous
Next ❯

Citations

Nov 15, 2011·Seminars in Immunopathology·Kevin M Rigby, Frank R DeLeo
Feb 27, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N J VerkaikW J B van Wamel
May 28, 2013·International Journal of Pharmaceutics·C ColonnaI Genta
Jul 18, 2009·Nature Reviews. Microbiology·Michael Otto
Jul 31, 2010·Immunology and Allergy Clinics of North America·Peck Y Ong, Mark Boguniewicz
Jun 21, 2011·Immunological Reviews·Mark Boguniewicz, Donald Y M Leung
Aug 11, 2010·FEMS Microbiology Reviews·Brian HendersonMark A Williams
Jan 30, 2010·The Journal of Allergy and Clinical Immunology·Mark Boguniewicz, Donald Y M Leung
Jan 24, 2014·Infection and Immunity·Kenneth L PinkstonBarrett R Harvey
Sep 7, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Gordon Y C CheungMichael Otto
Nov 7, 2015·Microbiology Spectrum·Peter Chahales, David G Thanassi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Yukiko K Stranger-JonesOlaf Schneewind
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Alice G ChengDominique M Missiakas
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
E L BrownM G Bowden
The Journal of Experimental Medicine
Juliane Bubeck Wardenburg, Olaf Schneewind
The New England Journal of Medicine
Gregory J MoranEMERGEncy ID Net Study Group
© 2021 Meta ULC. All rights reserved